
Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.
Eluemuno R. Blyden, PhD, is the founder and CEO of AfriVax, Inc.

Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.

Published: January 2nd 2010 | Updated: